文献速递冠心病心力衰竭与心肌病

ECMO辅助下PCI治疗低射血分数慢性完全闭塞病变的疗效与安全性

[Efficacy and safety of extracorporeal membrane oxygenation-supported percutaneous coronary intervention in chronic coronary total occlusion patients with reduced left ventricular ejection fraction].
PubMed 文献 · Zhonghua Xin Xue Guan Bing Za Zhi · 2023-01-01

回顾性分析17例LVEF≤35%的CTO患者,在ECMO辅助下行PCI,术后LVEF显著提高,无院内死亡,出院后随访死亡3例。初步证明该策略可行、有效且安全。

要点

  • ECMO辅助下对低LVEF的CTO患者行PCI可行且安全。
  • 术后LVEF较术前显著提高,随访期进一步改善。
  • 术后血红蛋白下降>20 g/L常见,需注意监测。

核心结论

  • ECMO辅助下对低LVEF的CTO患者行PCI具有较好的安全性、有效性和可行性。

研究设计与样本

  • 回顾性分析2018年12月至2022年3月北部战区总医院17例术前LVEF≤35%且在ECMO辅助下接受PCI的CTO患者。

主要发现

  • 共17例患者,年龄(59.4±11.8)岁,男性14例,术前LVEF为(29.00±4.08)%。
  • 17例患者共29处CTO病变,对25处尝试开通,24处成功置入支架,每例至少开通1处,置入支架(4.6±1.3)枚。
  • 术后2.5(2.0,5.5)d LVEF升至(38.73±7.01)%,显著高于术前(P<0.001),无院内死亡。
  • 出院后随访360(120,394)d,死亡3例(3/17);出院后155(100,308)d LVEF为(41.80±7.32)%,显著高于术前(P<0.001)。
  • 术后8例血红蛋白下降>20 g/L,1例发生ECMO穿刺部位出血。

临床怎么用

  • 对于LVEF≤35%的CTO患者,可考虑在ECMO辅助下实施PCI。
  • 术后应监测血红蛋白变化及ECMO穿刺部位出血情况。

局限性

  • 本研究为单中心回顾性分析,样本量仅17例,结论需更大规模研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate the feasibility and safety of extracorporeal membrane oxygenation (ECMO)-supported percutaneous coronary intervention (PCI) in chronic coronary total occlusion (CTO) patients with reduced left ventricular ejection fraction (LVEF). Methods: The CTO patients with LVEF≤35% and undergoing CTO-PCI assisted by ECMO in the General Hospital of Northern Theater Command from December 2018 to March 2022 were enrolled in this study. The post-procedure complications, changes of LVEF from pre-procedure to post-procedure during hospitalization, and the incidence of all-cause mortality and changes of LVEF after discharge were assessed. Results: A total of 17 patients aged (59.4±11.8) years were included. There were 14 males. The pre-procedure LVEF of these patients were (29.00±4.08)%. Coronary angiography results showed that there were 29 CTO lesions in these 17 patients. There was 1 in left main coronary artery, 7 in left anterior descending artery, 11 in left circumflex artery, and 10 in right coronary artery. ECMO was implanted in all patients before procedure. Among 25 CTO lesions attempted to cross, 24 CTO were successfully implanted with stents. All patients underwent successful PCI for at least one CTO lesion. The number of drug-eluting stents implantation per patient were 4.6±1.3. After procedure, there were 8 patients with hemoglobin decreased>20 g/L, and 1 patient with ECMO-access-site related bleeding. The LVEF value at a median duration of 2.5 (2.0-5.5) days after procedure significantly increased to (38.73±7.01)% (P<0.001 vs. baseline). There were no in-hospital deaths. Patients were followed up for 360 (120, 394) days after discharge, 3 patients died (3/17). The LVEF value was (41.80±7.32)% at 155 (100, 308) days after discharge, which was significantly higher than the baseline value (P<0.001). Conclusion: The results of present study demonstrate that it is feasible, efficient and safe to perform ECMO)-supported CTO-PCI in CTO patients with reduced LVEF. 目的: 初步探讨体外膜肺氧合(ECMO)辅助下对左心室射血分数(LVEF)明显降低的冠状动脉慢性完全闭塞(CTO)病变患者行经皮冠状动脉介入治疗(PCI)的疗效及安全性。 方法: 回顾性分析2018年12月至2022年3月于北部战区总医院在ECMO辅助下接受PCI的术前LVEF≤35%的CTO病变患者的临床资料。观察患者术后并发症及LVEF变化情况,出院后随访全因死亡发生情况和LVEF的变化。 结果: 共入选17例患者,年龄(59.4±11.8)岁,其中男性14例。PCI前超声心动图测得患者的LVEF为(29.00±4.08)%。冠状动脉造影结果显示,17例患者共存在29处CTO病变,其中左主干CTO病变1例,前降支CTO病变7例,回旋支CTO病变11例,右冠状动脉CTO病变10例。全部患者PCI术前成功预置ECMO,对25处CTO病变进行了介入治疗,其中24处成功开通并置入支架。每例患者至少开通1处CTO病变,置入(4.6±1.3)枚支架。术后,8例患者的血红蛋白下降>20 g/L,1例发生了ECMO术区动脉穿刺部位出血。患者术后2.5(2.0,5.5)d复查超声心动图,LVEF为(38.73±7.01)%,显著高于术前水平(P<0.001)。无院内死亡发生。出院后随访360(120,394)d,随访期间死亡3例(3/17)。出院后155(100,308)d复查超声心动图,LVEF值提升至(41.80±7.32)%,显著高于术前水平(P<0.001)。 结论: 初步证明ECMO辅助下对低LVEF值冠心病患者CTO病变行PCI有较好的安全性、有效性和可行性。.

来源:Zhonghua Xin Xue Guan Bing Za Zhi,查看原文。版权归原作者所有。

引用

  1. Guan SY, Liang ZY, Qiu MH, et al. [Efficacy and safety of extracorporeal membrane oxygenation-supported percutaneous coronary intervention in chronic coronary total occlusion patients with reduced left ventricular ejection fraction]. Zhonghua Xin Xue Guan Bing Za Zhi. 2023. PMID: 37709716. doi:10.3760/cma.j.cn112148-20230808-00060

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。